Neonav ECG Tip Location System— 510(k) K260929
Substantially EquivalentNavi Medical Technologies
FDA 510(k) clearance K260929 for Neonav ECG Tip Location System, Substantially Equivalent on 2026-04-17. Applicant: Navi Medical Technologies. Device class: 2.
Summary
Navi Medical Technologies' Neonav ECG Tip Location System is filed under product code LJS (Catheter, Intravascular, Therapeutic, Long-Term Greater Than 30 Days). The record doesn't describe the system beyond its name and that code name.
Class II, 21 CFR 880.5970. The record lists General Hospital as the classification panel, but the Cardiovascular review panel handled this Special 510(k).
Navi Medical Technologies filed from Carlton, Australia. Review took 28 calendar days (March 20 to April 17, 2026).
Clearance details
- Applicant
- Navi Medical Technologies
- Product code
- Product code LJS
- Device class
- Class 2
- Regulation
- 21 CFR 880.5970
- Advisory panel
- General Hospital
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Special
- Location
- Carlton, AU
Recent devices under product code LJS
view all- K260080 — Pro-Line XL Power Injectable Central Venous Catheter and Pro-Line XL Tunneler
- K252373 — BioFlo Hybrid PICC with ENDEXO Technology and PASV Valve Technology +6 more
- K252792 — PM2 System with ECGuide Connector
- K243458 — HydroPICC 4Fr Single Lumen Marked catheter, 130 cm guidewire - Basic Kit (70001301) +5 more
- K251212 — Dual Lumen 5Fr HydroPICC Catheter (PICC-251CM) (PICC-251CM); Dual Lumen 5Fr HydroPICC Catheter (PICC-252CM) (PICC-252CM)
More clearances from Navi Medical Technologies
view allAdverse events under product code LJS
product code LJS- Death
- 31
- Injury
- 2,791
- Malfunction
- 18,374
- Other
- 5
- Total
- 21,201
Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →
Data sourced from openFDA. This site is unofficial and independent of the FDA.